Clinical Trials
2 trialsNCT03739554 2024-01-25
CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL
Cyclacel Pharmaceuticals, Inc.
Phase 1 Completed
NCT04983810 2024-01-25
A Study to Investigate Fadraciclib (CYC065), in Subjects With Advanced Solid Tumors and Lymphoma
Cyclacel Pharmaceuticals, Inc.
Phase 1/2 Unknown